Loading...
Loading...
Omeros Corporation
OMER today
announced that the U.S. Food and Drug Administration (FDA) confirmed its
agreement with the Pediatric Study Plan (PSP) proposed by Omeros to study the
use of OMS302 in pediatric patients undergoing primary cataract extraction.
The FDA also issued a Written Request consistent with the PSP, which means
that successful completion of the PSP would make OMS302 eligible for an
additional six months of marketing exclusivity in the U.S. Added to standard
irrigation solution used during ophthalmological procedures, OMS302 is Omeros'
proprietary PharmacoSurgery^® product designed to maintain intraoperative
mydriasis (pupil dilation), prevent surgically induced miosis (pupil
constriction), and reduce postoperative pain resulting from cataract and other
lens replacement surgery.
As announced in July, the European Medicines Agency approved Omeros' Pediatric
Investigation Plan to study the use of OMS302 in pediatric patients, which is
expected to lead to additional marketing exclusivity in Europe. Omeros has
OMS302 marketing applications under review in the U.S. and Europe with
anticipated market launch in 2014. Results of the pediatric studies are
expected to be available during the post marketing period.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in